Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Metadata
Title
Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2
Authors
C. A. Kruse
Linda Cepeda
Betty Owens
Stephen D. Johnson
John Stears
Kevin O. Lillehei
Publication date
01-11-1997
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/1997
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050405

Other articles of this Issue 2/1997

Cancer Immunology, Immunotherapy 2/1997 Go to the issue

SHORT COMMUNICATION

The antitumor effects of levamisole in mice are mediated by NC-1.1+ cells

ORIGINAL ARTICLE

Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice

ERRATUM

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

ORIGINAL ARTICLE

Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope

ORIGINAL ARTICLE

Active and indolent chronic lymphocytic leukaemia – immune and hormonal peculiarities

ORIGINAL ARTICLE

Intrapleural instillation of interferon γ in patients with malignant pleurisy due to lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits